World's Best Scientists 2026 revealed!

D-Index & Metrics

Molecular Biology

D-Index
66
Citations
20479
World Ranking
1604
National Ranking
812

Frank Rigo publication distribution in Molecular Biology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Molecular Biology in 2026. The highlighted bar marks where Frank Rigo sits on this spectrum.

47–56 publications: 7 scientists 57–66 publications: 17 scientists 67–76 publications: 65 scientists 77–86 publications: 90 scientists 87–96 publications: 125 scientists 97–106 publications: 131 scientists 107–116 publications: 162 scientists 117–126 publications: 177 scientists 127–136 publications: 158 scientists 137–146 publications: 158 scientists 147–156 publications: 146 scientists 157–166 publications: 159 scientists 167–176 publications: 131 scientists 177–186 publications: 110 scientists 187–196 publications: 112 scientists 197–206 publications: 100 scientists 207–216 publications: 89 scientists 217–226 publications: 98 scientists 227–236 publications: 74 scientists 237–246 publications: 72 scientists 247–256 publications: 63 scientists 257–266 publications: 53 scientists 267–276 publications: 54 scientists 277–286 publications: 49 scientists 287–296 publications: 52 scientists 297–306 publications: 43 scientists 307–316 publications: 46 scientists 317–326 publications: 41 scientists 327–336 publications: 42 scientists 337–346 publications: 31 scientists 347–356 publications: 28 scientists 357–366 publications: 29 scientists 367–376 publications: 26 scientists 377–386 publications: 24 scientists 387–396 publications: 24 scientists 397–406 publications: 14 scientists 407–416 publications: 13 scientists 417–426 publications: 20 scientists 427–436 publications: 12 scientists 437–446 publications: 20 scientists 447–456 publications: 11 scientists 457–466 publications: 10 scientists 467–476 publications: 14 scientists 477–486 publications: 14 scientists 487–496 publications: 10 scientists 497–506 publications: 13 scientists 507–516 publications: 13 scientists 517–526 publications: 2 scientists 527–536 publications: 4 scientists 537–546 publications: 6 scientists 547–556 publications: 8 scientists 557–563 publications: 6 scientists 564+ publications: 100 scientists
47 publications 564+

This scientist: 184 publications — 53rd percentile

53% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 564 publications or more.

Frank Rigo D-index placement in Molecular Biology in 2026

The chart shows the D-index (discipline H-index) distribution of Molecular Biology scientists ranked by Research.com in 2026. The highlighted bar marks where Frank Rigo sits on this spectrum.

40–41 D-Index: 36 scientists 42–43 D-Index: 101 scientists 44–45 D-Index: 115 scientists 46–47 D-Index: 121 scientists 48–49 D-Index: 118 scientists 50–51 D-Index: 130 scientists 52–53 D-Index: 106 scientists 54–55 D-Index: 116 scientists 56–57 D-Index: 113 scientists 58–59 D-Index: 129 scientists 60–61 D-Index: 120 scientists 62–63 D-Index: 105 scientists 64–65 D-Index: 131 scientists 66–67 D-Index: 95 scientists 68–69 D-Index: 97 scientists 70–71 D-Index: 106 scientists 72–73 D-Index: 83 scientists 74–75 D-Index: 89 scientists 76–77 D-Index: 77 scientists 78–79 D-Index: 70 scientists 80–81 D-Index: 73 scientists 82–83 D-Index: 60 scientists 84–85 D-Index: 48 scientists 86–87 D-Index: 45 scientists 88–89 D-Index: 50 scientists 90–91 D-Index: 31 scientists 92–93 D-Index: 51 scientists 94–95 D-Index: 43 scientists 96–97 D-Index: 38 scientists 98–99 D-Index: 39 scientists 100–101 D-Index: 41 scientists 102–103 D-Index: 29 scientists 104–105 D-Index: 33 scientists 106–107 D-Index: 35 scientists 108–109 D-Index: 20 scientists 110–111 D-Index: 38 scientists 112–113 D-Index: 19 scientists 114–115 D-Index: 28 scientists 116–117 D-Index: 13 scientists 118–119 D-Index: 23 scientists 120–121 D-Index: 16 scientists 122–123 D-Index: 15 scientists 124–125 D-Index: 11 scientists 126–127 D-Index: 21 scientists 128–129 D-Index: 7 scientists 130–131 D-Index: 13 scientists 132–133 D-Index: 14 scientists 134–135 D-Index: 17 scientists 136–137 D-Index: 9 scientists 138–139 D-Index: 8 scientists 140–141 D-Index: 16 scientists 142–143 D-Index: 7 scientists 144 D-Index: 7 scientists 145+ D-Index: 100 scientists
40 D-Index 145+

This scientist: 66 D-Index — 48th percentile

48% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 145 D-Index or more.

Overview

Frank Rigo is affiliated with Ionis Pharmaceuticals in the United States. Their research focuses primarily on biochemistry, genetics, and molecular biology, with a significant emphasis on molecular biology, genetics, and neurology. The scientist's work is distributed across several subfields of study including cellular and molecular neuroscience and cancer research.

Their research portfolio includes topics such as RNA research and splicing, amyotrophic lateral sclerosis (ALS) research, RNA modifications and cancer, neurogenetic and muscular disorders research, genetic neurodegenerative diseases, genetics and neurodevelopmental disorders, and RNA regulation and disease.

Frank Rigo has published extensively in various scientific venues. The most frequent publication venues include:

  • bioRxiv (Cold Spring Harbor Laboratory)
  • Science Translational Medicine
  • Human Molecular Genetics
  • Nucleic Acids Research
  • Cancer Research

Among their recent scientific papers are:

  • Mechanism of STMN2 cryptic splice-polyadenylation and its correction for TDP-43 proteinopathies, 2023, Science
  • C9orf72 poly(GR) aggregation induces TDP-43 proteinopathy, 2020, Science Translational Medicine
  • G4C2 Repeat RNA Initiates a POM121-Mediated Reduction in Specific Nucleoporins in C9orf72 ALS/FTD, 2020, Neuron
  • Cholesterol-functionalized DNA/RNA heteroduplexes cross the blood-brain barrier and knock down genes in the rodent CNS, 2021, Nature Biotechnology
  • Nuclear accumulation of CHMP7 initiates nuclear pore complex injury and subsequent TDP-43 dysfunction in sporadic and familial ALS, 2021, Science Translational Medicine

Frequent coauthors contributing to Frank Rigo's research outputs include:

  • Paymaan Jafar-Nejad
  • Karen Ling
  • C. Frank Bennett
  • Armand Soriano
  • Michaela Jackson

Best Publications

  • Robust transcriptome-wide discovery of RNA-binding protein binding sites with enhanced CLIP (eCLIP)

    Eric L Van Nostrand;Gabriel A Pratt;Alexander A Shishkin;Chelsea Gelboin-Burkhart

  • RNA Toxicity from the ALS/FTD C9ORF72 Expansion Is Mitigated by Antisense Intervention

    Christopher J. Donnelly;Ping-Wu Zhang;Jacqueline T. Pham;Aaron R. Haeusler

  • Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study

    Richard S Finkel;Claudia A Chiriboga;Jiri Vajsar;John W Day

  • Targeting RNA Foci in iPSC-Derived Motor Neurons from ALS Patients with a C9ORF72 Repeat Expansion

    Dhruv Sareen;Jacqueline G. O’Rourke;Pratap Meera;A. K. M. G. Muhammad

  • Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model

    Yimin Hua;Kentaro Sahashi;Frank Rigo;Gene Hung

  • Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model

    Yimin Hua;Kentaro Sahashi;Gene Hung;Frank Rigo

  • Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration

    Clotilde Lagier-Tourenne;Michael Baughn;Frank Rigo;Shuying Sun

  • Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice

    Lindsay A. Becker;Brenda Huang;Gregor Bieri;Rosanna Ma

  • Gain of Toxicity from ALS/FTD-Linked Repeat Expansions in C9ORF72 Is Alleviated by Antisense Oligonucleotides Targeting GGGGCC-Containing RNAs

    Jie Jiang;Jie Jiang;Qiang Zhu;Tania F. Gendron;Shahram Saberi

  • Antisense Oligonucleotides Delivered to the Mouse CNS Ameliorate Symptoms of Severe Spinal Muscular Atrophy

    Marco A. Passini;Jie Bu;Amy M. Richards;Cathrine Kinnecom

  • Towards a therapy for Angelman syndrome by targeting a long non-coding RNA

    Linyan Meng;Amanda J. Ward;Seung Chun;C. Frank Bennett

  • Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-dependent neurodegeneration.

    Ze’ev Melamed;Jone López-Erauskin;Michael W. Baughn;Ouyang Zhang

  • The long non-coding RNA Gomafu is acutely regulated in response to neuronal activation and involved in schizophrenia-associated alternative splicing.

    Guy Barry;J. A. Briggs;D. P. Vanichkina;E. M. Poth

  • Stress Granule Assembly Disrupts Nucleocytoplasmic Transport

    Ke Zhang;J. Gavin Daigle;Kathleen M. Cunningham;Alyssa N. Coyne

  • Antisense oligonucleotide therapy for spinocerebellar ataxia type 2

    Daniel R. Scoles;Pratap Meera;Matthew D. Schneider;Sharan Paul

  • Antisense reduction of tau in adult mice protects against seizures.

    Sarah L. DeVos;Dustin K. Goncharoff;Guo Chen;Carey S. Kebodeaux

  • Pharmacology of a Central Nervous System Delivered 2′-O-Methoxyethyl–Modified Survival of Motor Neuron Splicing Oligonucleotide in Mice and Nonhuman Primates

    Frank Rigo;Seung J. Chun;Daniel A. Norris;Gene Hung

  • Poly(GP) proteins are a useful pharmacodynamic marker for C9ORF72-associated amyotrophic lateral sclerosis

    Tania D Gendron;Jeannie Chew;Jeannette N. Stankowski;Lindsey R. Hayes

  • Reversal of phenotypes in MECP2 duplication mice using genetic rescue or antisense oligonucleotides

    Yehezkel Sztainberg;Hong-mei Chen;John W. Swann;John W. Swann;Shuang Hao

  • Rescue of hearing and vestibular function by antisense oligonucleotides in a mouse model of human deafness

    Jennifer J Lentz;Francine M Jodelka;Anthony J Hinrich;Kate E McCaffrey

Frequent Co-Authors

C. Frank Bennett
C. Frank Bennett Ionis Pharmaceuticals (United States)
Adrian R. Krainer
Adrian R. Krainer Cold Spring Harbor Laboratory
David L. Spector
David L. Spector Cold Spring Harbor Laboratory
Jeffrey D. Rothstein
Jeffrey D. Rothstein Johns Hopkins University
David R. Corey
David R. Corey The University of Texas Southwestern Medical Center
Stefan M. Pulst
Stefan M. Pulst University of Utah
Don W. Cleveland
Don W. Cleveland University of California, San Diego
Gene W. Yeo
Gene W. Yeo University of California, San Diego
Nicolas G. Bazan
Nicolas G. Bazan Louisiana State University
Eric E. Swayze
Eric E. Swayze Ionis Pharmaceuticals (United States)

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Molecular Biology opens doors to diverse healthcare and science careers, many of which now offer flexible online education options. For students interested in communication sciences, there are asha accredited online slp programs that meet professional standards and can be completed at your own pace. These programs are ideal for those looking to become certified Speech-Language Pathologists.

If your background isn’t in communication science, you might benefit from transition to SLP master’s for non-CSD majors bridge programs. These options allow non-science and non-SLP graduates to enter the field without repeating undergraduate coursework.

Students considering a move to patient care can find accelerated nursing programs for non nurses, which are designed to quickly prepare graduates for the nursing profession. These intensive courses often combine online learning with onsite clinical experiences.

Advanced roles, such as psychiatric nurse practitioners, can offer lucrative career outcomes. For details on salary trends and job outlook, see the comprehensive data on psychiatric mental health nurse practitioner salary across different states.

Best Scientists Citing Frank Rigo

Trending Scientists

Recently Published Articles